Effects of glucagon-like peptide-1 (7-36) on antro-pyloro-duodenal motility

• US 6,579,851 B2
• Filed: 03/14/2001
• Issued: 06/17/2003
• Est. Priority Date: 03/14/2000
• Status: Expired due to Fees

• Current Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Schirra, Joerg, Goeke, Burkhard
• Primary Examiner(s): Weber, Jon P.
• Application Number:
  US09/805,507
• Publication Number:
  US 20020098195A1
• Time in Patent Office: 825 Days
• Field of Search: 514/12
• US Class Current: 514/11.7
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/12 Antidiarrhoeals
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/36 Opioid-abuse
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Abstract

The present invention provides an effective method for inhibiting antro-duodenal motility in healthy subjects and patients suffering from various disorders, without the side effects associated with other pharmaceutical compositions. GLP1(7-36)amide slows antro-duodenal motility and may be used for the treatment or prevention of gastrointestinal disorders such as diarrhea, postoperative dumping syndrome and irritable bowel syndrome, and also premedication in endoscopic procedures.

Claims

1. A method of inhibiting antro-duodenal motility in a patient in need thereof, which comprises parenterally administering to the patient a therapeutically effective amount of GLP-1(7-36)amide, in a dose of from about 0.4-1.2 pmol/kg/min.

2. The method of claim 1 whereby the GLP-1(7-36)amide is administered in combination with another antimotility agent.

3. A method of inhibiting antro-duodenal motility in a patient in need thereof, which comprises intravenously administering to the patient a therapeutically effective amount of GLP-1(7-36)amide in a dose of about 0.4 pmol/kg/min.

4. A method of inhibiting antro-duodenal motility in a patient in need thereof, which comprises intravenously administering to the patient a therapeutically effective amount of GLP-1(7-36)amide, in a dose of about 0.4 pmol/kg/min, and further providing that the GLP1(7-36)amide is administered in combination with another antimotility agent.

5. A method of reducing antro-duodenal motility in a patient in need thereof, which comprises intravenously administering to the patient a therapeutically effective amount of GLP-1(7-36)amide, in a dose of from about 0.4-1.2 pmol/kg/min, whereby the antral motility in the patient is reduced to 12.6±

2.8 or less, and the duodenal motility in the patient is reduced to 36.0±

14.7 or less.